Vijay Samant
Director/Board Member bij Xiconic Pharmaceuticals LLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Albert Marchio | M | 72 | 4 jaar | |
Aaron Fox-Collis | M | - | 4 jaar | |
Patricia Russo | F | 71 | 29 jaar | |
Elaine Heron | M | 76 | 22 jaar | |
Brian Mueller | M | 50 | 22 jaar | |
Caroline Litchfield | F | 55 | 34 jaar | |
George Bickerstaff | M | 68 |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 15 jaar |
Donald Quest | M | 83 |
The Trustees of Columbia University in The City of New York
| 48 jaar |
Brian Pusch | M | - |
Xiconic Pharmaceuticals LLC
| - |
Nancy Seretta | F | - | 8 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Robert P. Luciano | M | - | 23 jaar | |
Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 jaar |
Richard Kogan | M | 81 | 21 jaar | |
Andrew Sklawer | M | 41 | 14 jaar | |
Kenneth Frazier | M | 69 | 30 jaar | |
P. Vagelos | M | 94 | 19 jaar | |
Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 6 jaar |
Gary Lyons | M | 73 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 26 jaar |
Julie Smith | F | 53 | - | |
Paul Grint | M | 66 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 4 jaar |
Raymond Gilmartin | M | 82 | 2 jaar | |
Suzanne Bruhn | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 jaar |
Deepak Chadha | M | 54 | 7 jaar | |
George Morrow | M | 72 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 19 jaar |
Joseph Romanelli | M | 50 | 19 jaar | |
Frank Lanza | M | 62 | - | |
Shashank N. Desai | M | - |
University of Mumbai
| 7 jaar |
Keith D. Hall | M | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 15 jaar |
Reginald Hardy | M | 64 | 14 jaar | |
Kenneth F. Bartizal | M | 72 | 20 jaar | |
Larry Smith | M | 63 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 16 jaar |
Larry G. Edwards | M | 52 | 15 jaar | |
Bob H. Campbell | M | 86 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 10 jaar |
Yazdi Piroj Dandiwala | M | 73 |
University of Mumbai
| 10 jaar |
Alan R. Engbring | M | - |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 17 jaar |
Narendra Damodar Jadhav | M | 71 |
University of Mumbai
| 6 jaar |
Anthony W. D'Souza | M | - |
University of Mumbai
| 5 jaar |
Igor Bilinsky | M | 51 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 jaar |
Joshua Grass | M | - | 14 jaar | |
David Gionco | M | 63 | 3 jaar | |
Jill Broadfoot | F | 63 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 9 jaar |
Rajendra Kumar Aneja | M | 74 |
University of Mumbai
| 6 jaar |
Alka Marezban Bharucha | F | 67 |
University of Mumbai
| 7 jaar |
Gary Davis | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
Ramamurthy Viraraghavan | M | 70 |
University of Mumbai
| 6 jaar |
Joshua S. Rubenstein | M | - |
The Trustees of Columbia University in The City of New York
| 7 jaar |
Girish Nadkarni | M | - |
University of Mumbai
| 7 jaar |
Robert Brown | M | 62 | 4 jaar | |
Mammen P. Mammen | M | 60 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
Anders Klein | M | 71 |
The Trustees of Columbia University in The City of New York
| 6 jaar |
David E. Bosher | M | 70 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 jaar |
Bharat Kumar Khaitan | M | 69 |
University of Mumbai
| 6 jaar |
Maria Matesanz | F | - |
The Trustees of Columbia University in The City of New York
| 5 jaar |
Raymond Anderson | M | 82 | 4 jaar | |
Ben Golub | M | 66 |
MIT Sloan School of Management
| 3 jaar |
Stephen Sherwin | M | 75 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 2 jaar |
Fred W. Hill | M | 73 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
Caroline Dorsa | F | 64 | 22 jaar | |
Richard Henriques | M | 68 | 27 jaar | |
Louis C. Drapeau | M | 79 | 3 jaar | |
Jill Marie Church | F | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
Laura Sepp-Lorenzino | M | 63 | 15 jaar | |
Anthony Alan Ramos | M | 57 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 14 jaar |
William Harrison | M | 80 | - | |
Anne Tatlock | F | 84 | - | |
David R. McAvoy | M | 62 | 4 jaar | |
John J Horan | M | - | 6 jaar | |
Donald S. Brooks | M | 88 | - | |
Richard M. Beleson | M | 70 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 6 jaar |
Thomas Shenk | M | 77 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 4 jaar |
Paul K. Ross | M | - | - | |
M. Scott Salka | M | 62 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 jaar |
Fredric D. Price | M | 78 | 4 jaar | |
Dan Veru | M | 62 | 8 jaar | |
Richard Markham | M | 73 | 20 jaar | |
Wendy Yarno | F | 69 | 9 jaar | |
David C. Kaslow | M | 65 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
Robert C. Merton | M | 79 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 17 jaar |
Carolyn Nannini Dolan | F | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
John R. Rehayem | M | - |
The Trustees of Columbia University in The City of New York
| 6 jaar |
Marino Carol | F | - | 8 jaar | |
Mitaram Ramlal Jangid | M | 67 |
University of Mumbai
| 4 jaar |
Himanshu Patel | M | 71 |
University of Mumbai
| 4 jaar |
Vasudev Krishna Murti | M | 72 |
University of Mumbai
| 4 jaar |
Madhu Rama Chandra Rao | M | 72 |
University of Mumbai
| 4 jaar |
Mayank D. Sampat | M | 68 |
University of Mumbai
| 4 jaar |
Dilipkumar Mulchand Lotia | M | - |
University of Mumbai
| 4 jaar |
Santosh Kekre | M | 67 |
University of Mumbai
| 4 jaar |
Amarjit Singh | M | 74 |
University of Mumbai
| 4 jaar |
Himanshu Chaitanya Patel | M | 70 |
University of Mumbai
| 4 jaar |
John W. Wallen | M | 66 | 6 jaar | |
Anil D. Harish | M | 70 |
University of Mumbai
| 3 jaar |
Rahul Merchant | M | 67 |
University of Mumbai
| 4 jaar |
William D. Ju | M | 67 | 6 jaar | |
George Abercrombie | M | 69 | 10 jaar | |
Srikant T. Madhav Datar | M | 70 |
University of Mumbai
| 4 jaar |
Anand R. Baichwal | M | 69 |
University of Mumbai
| 4 jaar |
Sanjay Subhedar | M | - |
University of Mumbai
| 4 jaar |
Mahendra Gupta | M | 68 |
University of Mumbai
| 4 jaar |
Sunilkumar Dayama | M | 68 |
University of Mumbai
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 74 | 74.00% |
India | 25 | 25.00% |
Zuid-Korea | 1 | 1.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Vijay Samant
- Persoonlijk netwerk